Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 3/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499135 | 0.87 | CYP2C19 (0.44) | CYP2C19HSD17B10GDAKDM4ELMNA | |
| SCHEMBL15782808 | 0.82 | HSD17B10 (0.47) | CYP2C19HSD17B10KDM4ELMNASMN1; SMN2 | |
| SCHEMBL16399189 | 0.82 | CYP2C19 (0.47) | CYP2C19HSD17B10GDAKDM4ELMNA | |
| SCHEMBL16398756 | 0.81 | CYP2C19 (0.46) | CYP2C19HSD17B10GDAKDM4ELMNA | |
| SCHEMBL23213731 | 0.78 | KDM4E (0.45) | CYP2C19HSD17B10KDM4ELMNATSHR | |
| SCHEMBL10278987 | 0.77 | KDM4E (0.59) | HSD17B10KDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7435782 | 0.77 | CYP2C19 (0.42) | CYP2C19HSD17B10GDALMNAXDH | |
| SCHEMBL3025277 | 0.75 | — | — | |
| SCHEMBL4954812 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL10712747 | 0.74 | GDA (0.45) | CYP2C19HSD17B10GDAKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CYP2C19 195/4885HSD17B10 1809/4885GDA 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.